Nurix Therapeutics to Present Preclinical Data from Its Novel BTK Degrader (NX-2127)…
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that…